MRx0518 and Pembrolizumab Combination Study

Conditions:   Oncology;   Solid Tumor;   Non Small Cell Lung Cancer;   Renal Cell Carcinoma;   Melanoma;   Bladder Cancer Interventions:   Drug: MRx0518;   Drug: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA] Sponsors:   4DPharma PLC;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials